

Literatur

- [1] Maiwald M, Oehme R, March O et al. Transmission risk of *Borrelia burgdorferi* sensu lato from *Ixodes ricinus* ticks to humans in southwest Germany. *Epidemiol Infect* 1998; 121: 103–108. DOI: 10.1017/s0950268898008929
- [2] Hammers-Berggren S, Lebech AM, Karlsson M et al. Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis. *J Clin Microbiol* 1994; 32: 1519–1525. DOI: 10.1128/jcm.32.6.1519-1525.1994
- [3] Hilton E, Tramontano A, DeVoti J et al. Temporal study of immunoglobulin M seroreactivity to *Borrelia burgdorferi* in patients treated for Lyme borreliosis. *J Clin Microbiol* 1997; 35: 774–776. DOI: 10.1128/jcm.35.3.774-776.1997
- [4] Kalish RA, McHugh G, Granquist J et al. Persistence of immunoglobulin M or immunoglobulin G antibody responses to *Borrelia burgdorferi* 10–20 years after active Lyme disease. *Clin Infect Dis* 2001; 33: 780–785. DOI: 10.1086/322669
- [5] Eiffert H, Hanefeld F, Thomssen R et al. Reinfection in Lyme borreliosis. *Infection* 1996; 24: 437–439. DOI: 10.1007/BF01713045
- [6] Steere AC. Seronegative Lyme disease. *JAMA* 1993; 270: 1369. DOI: 10.1001/jama.270.11.1369b
- [7] Lyme-Borreliose. Bd. 12. MiQ //Expertengremium Mikrobiologische-Infektiologische Qualitätsstandards (MiQ) Fachgruppe "Diagnostische Verfahren in der Mikrobiologie" der Deutschen Gesellschaft für Hygiene und Mikrobiologie (DGHM). Im Auftr. der Deutschen Gesellschaft für Hygiene und Mikrobiologie (DGHM). Hrsg. von H. Mauch. 2. Aufl. München: Elsevier Urban & Fischer; 2017
- [8] Fingerle, Volker, Dr., Hofmann. 013-044I_S2k_Kutane_Lyme_Borreliose_2024-06
- [9] Neuroborreliose, S3-Leitlinie, 2018
- [10] Fallon BA, Keilp JG, Corbera KM et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. *Neurology* 2008; 70: 992–1003. DOI: 10.1212/01.WNL.0000284604.61160.2d
- [11] Berende A, ter Hofstede HJM, Vos FJ et al. Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. *N Engl J Med* 2016; 374: 1209–1220. DOI: 10.1056/NEJMoa1505425
- [12] Krupp LB, Hyman LG, Grimson R et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. *Neurology* 2003; 60: 1923–1930. DOI: 10.1212/01.wnl.0000071227.23769.9e
- [13] Sjöwall J, Ledel A, Ernerudh J et al. Doxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a randomized, prospective, cross-over study. *BMC Infect Dis* 2012; 12: 186. DOI: 10.1186/1471-2334-12-186
- [14] Treib J, Fernandez A, Haass A et al. Clinical and serologic follow-up in patients with neuroborreliosis. *Neurology* 1998; 51: 1489–1491. DOI: 10.1212/wnl.51.5.1489
- [15] Ljøstad U, Mygland A. Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. *Eur J Neurol* 2010; 17: 118–123. DOI: 10.1111/j.1468-1331.2009.02756.x
- [16] Berglund J, Stjernberg L, Ornstein K et al. 5-y Follow-up study of patients with neuroborreliosis. *Scand J Infect Dis* 2002; 34: 421–425. DOI: 10.1080/00365540110080421
- [17] Eikeland R, Mygland Å, Herlofson K et al. Risk factors for a non-favorable outcome after treated European neuroborreliosis. *Acta Neurol Scand* 2013; 127: 154–160. DOI: 10.1111/j.1600-0404.2012.01690.x
- [18] Oliveira CR, Shapiro ED. Update on persistent symptoms associated with Lyme disease. *Curr Opin Pediatr* 2015; 27: 100–104. DOI: 10.1097/MOP.0000000000000167
- [19] Feder HM, Johnson BJB, O'Connell S et al. A critical appraisal of "chronic Lyme disease". *N Engl J Med* 2007; 357: 1422–1430. DOI: 10.1056/NEJMra072023
- [20] Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. *Expert Rev Anti Infect Ther* 2014; 12: 1103–1135. DOI: 10.1586/14787210.2014.940900
- [21] Cameron DJ. Proof that chronic lyme disease exists. *Interdiscip Perspect Infect Dis* 2010; 2010: 876450. DOI: 10.1155/2010/876450
- [22] Perronne C. Critical review of studies trying to evaluate the treatment of chronic Lyme disease. *Presse Med* 2015; 44: 828–831. DOI: 10.1016/j.lpm.2015.06.002
- [23] Baker PJ. The pain of "chronic Lyme disease": moving the discourse in a different direction. *FASEB J* 2012; 26: 11–12. DOI: 10.1096/fj.11-192898
- [24] Halperin JJ. Chronic Lyme disease: misconceptions and challenges for patient management. *Infect Drug Resist* 2015; 8: 119–128. DOI: 10.2147/IDR.S66739
- [25] Johnson L, Wilcox S, Mankoff J et al. Severity of chronic Lyme disease compared to other chronic conditions: a quality of life survey. *PeerJ* 2014; 2: e322. DOI: 10.7717/peerj.322
- [26] Vrethem M, Hellblom L, Widlund M et al. Chronic symptoms are common in patients with neuroborreliosis – a questionnaire follow-up study. *Acta Neurol Scand* 2002; 106: 205–208. DOI: 10.1034/j.1600-0404.2002.01358.x
- [27] Mund M, Uhlenbusch N, Rillig F et al. Psychological distress of adult patients consulting a center for rare and undiagnosed diseases: a cross-sectional study. *Orphanet J Rare Dis* 2023; 18: 82. DOI: 10.1186/s13023-023-02669-7
- [28] Shire Human Genetic Therapies. Rare Disease Impact Report: Insights from patients and the medical community. unter: https://globalgenes.org/wp-content/uploads/2013/04/ShireReport-1.pdf?utm_source=chatgpt.com
- [29] Association AP. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; 2013. DOI: 10.1176/appi.books.9780890425596
- [30] World Health Organization. International statistical classification of diseases and related health problems (11th ed.) unter: <https://icd.who.int/>
- [31] International statistical classification of diseases and related health problems. 2. Aufl. Geneva; 2004
- [32] Kolb-Niemann B, Kruse J. Bedeutung der psychosomatischen Medizin für Menschen mit seltenen Erkrankungen. *Internist (Berl)* 2019; 60: 638–643. DOI: 10.1007/s00108-019-0613-8